The Changing Epidemiology of Meningococcal Disease

Infectious Disease Clinics of North America

Volumn 29, Issue 4, 2015, Pages 667-677

  Cohn, Amanda ^a   MacNeil, Jessica ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Meningococcal disease; Neisseria meningitidis; Vaccination

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCUS TETANUS VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN G; RIFAMPICIN; VANCOMYCIN; VACCINE;

ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; BACTERIUM CARRIER; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CHEMOPROPHYLAXIS; DISEASE ERADICATION; EPIDEMIC; HUMAN; INCIDENCE; INFECTION CONTROL; MASS IMMUNIZATION; MENINGOCOCCEMIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PREVALENCE; REVIEW; SINGLE DRUG DOSE; ADOLESCENT; AFRICA; CHILD; ENDEMIC DISEASES; IMMUNOLOGY; MENINGITIS, MENINGOCOCCAL; MICROBIOLOGY; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADOLESCENT; AFRICA; CHILD; DISEASE OUTBREAKS; ENDEMIC DISEASES; HUMANS; INCIDENCE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; RISK FACTORS; UNITED STATES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84947734993     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.08.002     Document Type: Review

References (32)

1. Cohn A.C., MacNeil J.R., Harrison L.H., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50(2):184-191.
2. Christensen H., May M., Bowen L., et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(12):853-861.
3. Cohn A.C., MacNeil J.R., Clark T.A., et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013, 62(RR-2):1-28.
4. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-7):1-21.
5. Folaranmi T., Rubin L., Martin S.W., et al. Use of serogroup B meningococcal vaccines in persons aged >/=10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015, 64(22):608-612.
6. Harrison L.H., Shutt K.A., Schmink S.E., et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010, 201(8):1208-1224.
7. Mayer L.W., Reeves M.W., Al-Hamdan N., et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185(11):1596-1605.
8. Ladhani S.N., Lucidarme J., Newbold L.S., et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis 2012, 18(1):63-70.
9. Campbell H., Saliba V., Borrow R., et al. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill 2015, 20(28):1-5.
10. Trotter C.L., Andrews N.J., Kaczmarski E.B., et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364(9431):365-367.
11. Novak R.T., Kambou J.L., Diomande F.V., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12(10):757-764.
12. Daugla D.M., Gami J.P., Gamougam K., et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014, 383(9911):40-47.
13. Funk A., Uadiale K., Kamau C., et al. Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. PLoS Curr 2014, 6. Available at:. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322033/.
14. Rosenstein N.E., Perkins B.A., Stephens D.S., et al. Meningococcal disease. N Engl J Med 2001, 344(18):1378-1388.
15. Wu H.M., Harcourt B.H., Hatcher C.P., et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009, 360(9):886-892.
16. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl 2):B51-B63.
17. Jackson L.A., Schuchat A., Reeves M.W., et al. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995, 273(5):383-389.
18. Mandal S., Wu H.M., MacNeil J.R., et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis 2013, 57(3):344-348.
19. McNamara L.A., Shumate A.M., Johnsen P., et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 2015, 135(5):798-804.
20. Trotter C.L., Gay N.J., Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006, 134(3):556-566.
21. Caugant D.A., Hoiby E.A., Magnus P., et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994, 32(2):323-330.
22. Kristiansen P.A., Diomande F., Wei S.C., et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011, 18(3):435-443.
23. Reagan-Steiner S., Yankey D., Jeyarajah J., et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2014. MMWR 2015, 64(29):784-792.
24. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33(4):530-541.
25. Giuliani M.M., Adu-Bobie J., Comanducci M., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103(29):10834-10839.
26. MenB-4C, Bexsero [package insert]. Available at: . Accessed September 28, 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf.
27. MenB-FHbp, Trumenba [package insert]. Available at: . Accessed September 28, 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf.
28. LaForce M., Ravenscroft N., Mamoudou D., et al. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl 2):B13-B19.
29. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30(6):1049-1057.
30. Kristiansen P.A., Ba A.K., Ouedraogo A.S., et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect Dis 2014, 14:663.
31. Gamougam K., Daugla D.M., Toralta J., et al. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. Emerg Infect Dis 2015, 21(1):115-118.
32. Delrieu I., Yaro S., Tamekloe T.A.S., et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011, 6(5):e19513.